Related Experiment Video
Updated: Aug 21, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Lipoprotein (a) in patients on hemodialysis
José Antonio Díaz-Peromingo1, Dolores Güimil Carbajal, Ana Albán-Salgado
1Department of Internal Medicine, Hospital da Barbanza, Riveira, Spain. jadiazperomingo@mundo-r.com
Lipoprotein (a) [Lp(a)] may produce thrombogenic effects by modulating the fibrinolytic system. Elevated levels of Lp(a) have also been associated with an increased risk for atherosclerosis. Because atherosclerosis is more prevalent among patients with end-stage renal disease, the role of Lp(a) among patients on hemodialysis is analyzed. Twenty patients were studied. Lp(a) was measured before and after a hemodialysis session and before the following session. Between the first and second measures there was no statistical difference but when first and third measures were compared, a statistical difference (increase) was found. In conclusion, changes in Lp(a) levels were found and perhaps these changes are related to the episodic inflammation affecting patients on hemodialysis. The significance of these changes and the role in accelerating atherosclerosis in patients with end-stage renal disease are unknown.
Lipoprotein (a) [Lp(a)] may produce thrombogenic effects by modulating the fibrinolytic system. Elevated levels of Lp(a) have also been associated with an increased risk for atherosclerosis. Because atherosclerosis is more prevalent among patients with end-stage renal disease, the role of Lp(a) among patients on hemodialysis is analyzed. Twenty patients were studied. Lp(a) was measured before and after a hemodialysis session and before the following session. Between the first and second measures there was no statistical difference but when first and third measures were compared, a statistical difference (increase) was found. In conclusion, changes in Lp(a) levels were found and perhaps these changes are related to the episodic inflammation affecting patients on hemodialysis. The significance of these changes and the role in accelerating atherosclerosis in patients with end-stage renal disease are unknown.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hemodialysis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cholesterol: Significance and Regulation
Considering cholesterol and...
